A sub-unit of a protein that, when expressed, reverse the mutated gene effects responsible for Huntington's disease (HD) has been identified by researchers at University of California San Diego School of Medicine. HD is a fatal genetic disorder characterized by progressive deterioration of physical and mental abilities.
This was done by using an experimental co-culture approach in which two different types of neurons from a mouse model of HD are grown side-by-side, connecting to form critically impacted circuits. The findings are published online in the journal PNAS.
"Our experimental design provides an invaluable system for studying important cellular and molecular events underlying Huntington's disease," said first author Xiaobei Zhao, PhD, a post-doctoral scientist in the Department of Neurosciences at UC San Diego School of Medicine.
"Importantly, using this model provided evidence that expression of a single sub-unit of the TRiC protein, which inhibits the aggregation of mutant huntingtin proteins, rescued atrophy of striatal neurons. The next step is to test this in vivo. If the phenotype of the HD mouse model can be rescued, it's possible that TRiC could be used to treat Huntington's disease."
The corticostriatal pathway is a neuronal circuit connecting two parts of the brain: the outer, folded cerebral cortex where memory, thought, language and consciousness occur, and the underlying striatum -- a region responsible for, among other things, behavior and voluntary movement in response to social stimuli. Corticostriatal decline is a telltale indicator of HD.
In their study, Zhao, with senior author William Mobley, MD, PhD, chair and Distinguished Professor in the Department of Neurosciences, and colleagues cultured cortical and striatal neurons from an HD transgenic mouse model that expresses the human mutant huntingtin gene in a microfluidic chamber that allowed the cortical neurons to connect via axons to striatal neurons.
They found that the resulting circuits recapitulated several salient features of HD pathology, including reduced synaptic density and BDNF. Zhao stated "The new model and the ability to recreate the abnormal circuit is more physiologically relevant than many other models. Most important, it facilitates study of disease mechanisms and possible new disease-modifying treatments."